# Regulatory Post Marketing Surveillance Study on Nexavar®

> **NCT01012011** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2845 (actual)

## Conditions studied

- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT01012011
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-08
- **Target enrollment:** 2845 (ACTUAL)
- **Last updated:** 2015-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012011, "Regulatory Post Marketing Surveillance Study on Nexavar®". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01012011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*